Exclusion criteria included end-stage illness, dialysis, renal transplantation, severe pancreatic disorders, bowel obstruction or major surgery of the intestines before cohort entry, the diagnosis of drug misuse within one year of cohort entry, and the diagnosis of diseases (e.g., inflammatory bowel disease, neoplasms, or hernias) that could cause constipation or intestinal obstruction within 90 days of cohort entry
He highlights that the smaller dose in diabetics has also been shown to improve renal and cardiovascular outcomes, and that these outcomes are now being studied in non-diabetics
Thus, the drug is either absorbed systemically by blood vessels or cleared by mucociliary clearance [10]
There is virtually no published scientific evidence that proves taking smaller-than-standard doses of tirzepatide or semaglutide the active ingredients in Zepbound and Ozempic, respectively is safe or effective
Therapeutic strategies targeting iron homeostasis, lipid peroxidation, and immunoinflammatory regulation offer promising opportunities for the prevention and treatment of OA
